{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:47:54Z","timestamp":1794379674033,"version":"4.9.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-025-00670-x","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:02:21Z","timestamp":1764835341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Vitiligo"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Min","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-6430","authenticated-orcid":false,"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bellei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-1222","authenticated-orcid":false,"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Picardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"670_CR1","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","volume":"9","author":"J Akl","year":"2024","unstructured":"Akl, J. et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health 9, e386\u2013e396 (2024).","journal-title":"Lancet Public Health"},{"key":"670_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine, K., Eleftheriadou, V., Whitton, M. & van Geel, N. Vitiligo. Lancet 386, 74\u201384 (2015).","journal-title":"Lancet"},{"key":"670_CR3","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel, N. et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force part 1: towards a new management algorithm. J. Eur. Acad. Dermatol. Venereol. 37, 2173\u20132184 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR4","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine, K. et al. Revised classification\/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res. 25, E1\u2013E13 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR5","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau, K. et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J. Eur. Acad. Dermatol. Venereol. 36, 1831\u20131844 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","volume":"158","author":"K Gandhi","year":"2022","unstructured":"Gandhi, K. et al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol. 158, 43\u201350 (2022).","journal-title":"JAMA Dermatol."},{"key":"670_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/bjd\/ljae282","volume":"192","author":"V Eleftheriadou","year":"2024","unstructured":"Eleftheriadou, V., Ahmed, A., Nesnas, J. & Nagra, R. The lifetime risk and impact of vitiligo across sociodemographic groups: a UK population-based cohort study. Br. J. Dermatol. 192, 63\u201371 (2024).","journal-title":"Br. J. Dermatol."},{"key":"670_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/0378-6323.32708","volume":"73","author":"V Sehgal","year":"2007","unstructured":"Sehgal, V. & Srivastava, G. Vitiligo: compendium of clinico-epidemiological features. Indian J. Dermatol. Venereol. Leprol. 73, 149 (2007).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"670_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08337-4","volume":"10","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nat. Commun. 10, 391 (2019).","journal-title":"Nat. Commun."},{"key":"670_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1468-3083.2010.03847.x","volume":"25","author":"N van Geel","year":"2011","unstructured":"van Geel, N. et al. Different phenotypes of segmental vitiligo based on a clinical observational study. J. Eur. Acad. Dermatol. Venereol. 25, 673\u2013678 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR11","doi-asserted-by":"publisher","first-page":"8065765","DOI":"10.1155\/2016\/8065765","volume":"2016","author":"L Lazzeri","year":"2016","unstructured":"Lazzeri, L., Colucci, R., Cammi, A., Dragoni, F. & Moretti, S. Adult onset vitiligo: multivariate analysis suggests the need for a thyroid screening. BioMed. Res. Int. 2016, 8065765 (2016).","journal-title":"BioMed. Res. Int."},{"key":"670_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaad.2015.05.038","volume":"73","author":"EW Mu","year":"2015","unstructured":"Mu, E. W., Cohen, B. E. & Orlow, S. J. Early-onset childhood vitiligo is associated with a more extensive and progressive course. J. Am. Acad. Dermatol. 73, 467\u2013470 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jid.2019.06.131","volume":"140","author":"Y Jin","year":"2019","unstructured":"Jin, Y., Santorico, S. A. & Spritz, R. A. Pediatric to adult shift in vitiligo onset suggests altered environmental triggering. J. Investig. Dermatol. 140, 241\u2013243.e4 (2019).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archderm.1993.01680290066010","volume":"129","author":"PP Majumder","year":"1993","unstructured":"Majumder, P. P., Nordlund, J. J. & Nath, S. K. Pattern of familial aggregation of vitiligo. Arch. Dermatol. 129, 994\u2013998 (1993).","journal-title":"Arch. Dermatol."},{"key":"670_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"RA Spritz","year":"2017","unstructured":"Spritz, R. A. & Andersen, G. H. L. Genetics of vitiligo. Dermatol. Clin. 35, 245\u2013255 (2017).","journal-title":"Dermatol. Clin."},{"key":"670_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/bjd\/ljad196","volume":"189","author":"JH Han","year":"2023","unstructured":"Han, J. H. et al. Autoimmune, inflammatory, allergic and neuropsychiatric outcomes of offspring born to mothers with vitiligo: a nationwide Korean population-based birth cohort study. Br. J. Dermatol. 189, 488\u2013490 (2023).","journal-title":"Br. J. Dermatol."},{"key":"670_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jid.2020.06.004","volume":"141","author":"RA Spritz","year":"2021","unstructured":"Spritz, R. A. & Santorico, S. A. The genetic basis of vitiligo. J. Investig. Dermatol. 141, 265\u2013273 (2021).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pcmr.12848","volume":"33","author":"GHL Roberts","year":"2020","unstructured":"Roberts, G. H. L., Santorico, S. A. & Spritz, R. A. The genetic architecture of vitiligo. Pigment Cell Melanoma Res. 33, 8\u201315 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2024.09.007","author":"GHL Roberts","year":"2024","unstructured":"Roberts, G. H. L., Fain, P. R., Santorico, S. A. & Spritz, R. A. Inverse relationship between polygenic risk burden and age of onset of autoimmune vitiligo. Am. J. Hum. Genet. https:\/\/doi.org\/10.1016\/j.ajhg.2024.09.007 (2024).","journal-title":"Am. J. Hum. Genet."},{"key":"670_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkhateeb","year":"2003","unstructured":"Alkhateeb, A., Fain, P. R., Thody, A., Bennett, D. C. & Spritz, R. A. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res. 16, 208\u2013214 (2003).","journal-title":"Pigment Cell Res."},{"key":"670_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/bjd\/ljaf074","volume":"193","author":"B Delcoigne","year":"2025","unstructured":"Delcoigne, B., Lysell, J. & Askling, J. Incidence, stage and outcome of malignant melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks? Br. J. Dermatol. 193, 66\u201373 (2025).","journal-title":"Br. J. Dermatol."},{"key":"670_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","volume":"71","author":"A Paradisi","year":"2014","unstructured":"Paradisi, A. et al. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J. Am. Acad. Dermatol. 71, 1110\u20131116 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjd.12111","volume":"168","author":"HE Teulings","year":"2013","unstructured":"Teulings, H. E. et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br. J. Dermatol. 168, 162\u2013171 (2013).","journal-title":"Br. J. Dermatol."},{"key":"670_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaad.2024.11.043","volume":"92","author":"Y Schonmann","year":"2025","unstructured":"Schonmann, Y., Cohen, N. T. & Czarnowicki, T. Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: insights from a comprehensive cohort population-based study. J. Am. Acad. Dermatol. 92, 741\u2013752 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.04.013","author":"J Ferguson","year":"2023","unstructured":"Ferguson, J., Eleftheriadou, V. & Nesnas, J. Risk of melanoma and non-melanoma skin cancer in people with vitiligo: UK population-based cohort study. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2023.04.013 (2023).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/bjd.16703","volume":"179","author":"L Ban","year":"2018","unstructured":"Ban, L., Labbouz, S., Grindlay, D., Batchelor, J. M. & Ratib, S. Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis. Br. J. Dermatol. 179, 971\u2013972 (2018).","journal-title":"Br. J. Dermatol."},{"key":"670_CR27","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.jid.2018.03.1511","volume":"138","author":"W Wu","year":"2018","unstructured":"Wu, W. et al. Inverse relationship between vitiligo-related genes and skin cancer risk. J. Investig. Dermatol. 138, 2072\u20132075 (2018).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR28","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/ng.3680","volume":"48","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 48, 1418\u20131424 (2016).","journal-title":"Nat. Genet."},{"key":"670_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1365-2133.2012.11111.x","volume":"167","author":"N van Geel","year":"2012","unstructured":"van Geel, N. et al. Clinical significance of Koebner phenomenon in vitiligo. Br. J. Dermatol. 167, 1017\u20131024 (2012).","journal-title":"Br. J. Dermatol."},{"key":"670_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.det.2016.11.006","volume":"35","author":"JE Harris","year":"2017","unstructured":"Harris, J. E. Chemical-induced vitiligo. Dermatol. Clin. 35, 151\u2013161 (2017).","journal-title":"Dermatol. Clin."},{"key":"670_CR31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jaad.2021.02.083","volume":"86","author":"M Condamina","year":"2022","unstructured":"Condamina, M. et al. Factors associated with perceived stress in patients with vitiligo in the ComPaRe e-cohort. J. Am. Acad. Dermatol. 86, 696\u2013698 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/ijd.17148","volume":"63","author":"MSA Abadie","year":"2024","unstructured":"Abadie, M. S. A., Chaiyabutr, C., Patel, K. X. & Gawkrodger, D. J. Vitiligo and psychological stress: a hypothesis integrating the neuroendocrine and immune systems in melanocyte destruction. Int. J. Dermatol. 63, 841\u2013843 (2024).","journal-title":"Int. J. Dermatol."},{"key":"670_CR33","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.jid.2021.01.036","volume":"141","author":"H Bzioueche","year":"2021","unstructured":"Bzioueche, H. et al. Analysis of matched skin and gut microbiome of patients with vitiligo reveals deep skin dysbiosis: link with mitochondrial and immune changes. J. Investig. Dermatol. 141, 2280\u20132290 (2021).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR34","doi-asserted-by":"publisher","first-page":"1499035","DOI":"10.3389\/fmicb.2025.1499035","volume":"16","author":"Y Dou","year":"2025","unstructured":"Dou, Y. et al. Identification of disease-specific gut microbial markers in vitiligo. Front. Microbiol. 16, 1499035 (2025).","journal-title":"Front. Microbiol."},{"key":"670_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jid.2019.08.435","volume":"140","author":"ER Dellacecca","year":"2019","unstructured":"Dellacecca, E. R. et al. Antibiotics drive microbial imbalance and vitiligo development in mice. J. Invest. Dermatol. 140, 676\u2013687.e6 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/bjd\/ljad148","volume":"189","author":"H Bzioueche","year":"2023","unstructured":"Bzioueche, H. et al. Impact of house dust mite in vitiligo skin: environmental contribution to increased cutaneous immunity and melanocyte detachment. Br. J. Dermatol. 189, 312\u2013327 (2023).","journal-title":"Br. J. Dermatol."},{"key":"670_CR37","doi-asserted-by":"publisher","first-page":"1566267","DOI":"10.3389\/fmicb.2025.1566267","volume":"16","author":"C Yuan","year":"2025","unstructured":"Yuan, C. et al. Exploring the influence of gut microbiota metabolites on vitiligo through the gut-skin axis. Front. Microbiol. 16, 1566267 (2025).","journal-title":"Front. Microbiol."},{"key":"670_CR38","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1365-2133.2012.11198.x","volume":"167","author":"C Vrijman","year":"2012","unstructured":"Vrijman, C. et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br. J. Dermatol. 167, 1224\u20131235 (2012).","journal-title":"Br. J. Dermatol."},{"key":"670_CR39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"J Liu","year":"2003","unstructured":"Liu, J., Matangi, S., Malempati, Y., Nasir, A. & Rosmarin, D. Prevalence and association of autoimmune comorbidities among adults with vitiligo: a systematic literature review and meta-analysis of USA-based studies. Pigment Cell Res. 16, 208\u2013214 (2003).","journal-title":"Pigment Cell Res."},{"key":"670_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","volume":"143","author":"JH Lee","year":"2023","unstructured":"Lee, J. H. et al. Comorbidities in patients with vitiligo: a systematic review and meta-analysis. J. Investig. Dermatol. 143, 777\u2013789.e6 (2023).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0394-1","volume":"20","author":"H Yen","year":"2019","unstructured":"Yen, H. & Chi, C.-C. Association between psoriasis and vitiligo: a systematic review and meta-analysis. Am. J. Clin. Dermatol. 20, 31\u201340 (2019).","journal-title":"Am. J. Clin. Dermatol."},{"key":"670_CR42","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan, G. C. & Silverberg, J. I. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 151, 522\u2013528 (2015).","journal-title":"JAMA Dermatol."},{"key":"670_CR43","doi-asserted-by":"publisher","first-page":"42819","DOI":"10.2340\/actadv.v105.42819","volume":"105","author":"Y Wohl","year":"2025","unstructured":"Wohl, Y., Bentov, A., Drutin, Y., Maruani, A. & Mashiah, J. A threefold association between vitiligo and alopecia areata: results from a nationwide case-control observational study. Acta Derm. Venereol. 105, 42819 (2025).","journal-title":"Acta Derm. Venereol."},{"key":"670_CR44","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jaad.2020.12.029","volume":"85","author":"S-H Ma","year":"2021","unstructured":"Ma, S.-H., Ang, M.-D., Chang, Y.-T. & Dai, Y.-X. Association between vitiligo and hearing loss. J. Am. Acad. Dermatol. 85, 1465\u20131472 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.047","author":"DH Kim","year":"2025","unstructured":"Kim, D. H. et al. Ocular and auditory comorbidities in patients with vitiligo: a nationwide population-based study in the Republic of Korea. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.047 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-02777-9","volume":"23","author":"T LeWitt","year":"2023","unstructured":"LeWitt, T. et al. Ocular manifestations of vitiligo: a systematic review. BMC Ophthalmol. 23, 120 (2023).","journal-title":"BMC Ophthalmol."},{"key":"670_CR47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine, K. et al. Psychosocial effects of vitiligo: a systematic literature review. Am. J. Clin. Dermatol. 22, 757\u2013774 (2021).","journal-title":"Am. J. Clin. Dermatol."},{"key":"670_CR48","doi-asserted-by":"publisher","first-page":"2504082","DOI":"10.1080\/09546634.2025.2504082","volume":"36","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine, K. et al. Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global valiant survey. J. Dermatol. Treat. 36, 2504082 (2025).","journal-title":"J. Dermatol. Treat."},{"key":"670_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s13555-025-01401-6","volume":"15","author":"KA Hanson","year":"2025","unstructured":"Hanson, K. A. et al. Demographics and clinical characteristics among patients with distinct psychosocial burden profiles related to vitiligo: results of a latent class analysis. Dermatol. Ther. 15, 1195\u20131208 (2025).","journal-title":"Dermatol. Ther."},{"key":"670_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/13651501.2024.2382091","volume":"28","author":"M Turner","year":"2024","unstructured":"Turner, M. Neurobiological and psychological factors to depression. Int. J. Psychiatry Clin. Pr. 28, 114\u2013127 (2024).","journal-title":"Int. J. Psychiatry Clin. Pr."},{"key":"670_CR51","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/j.1468-3083.2010.03897.x","volume":"25","author":"YJ Lv","year":"2011","unstructured":"Lv, Y. J. et al. The polymorphism of catalase T\/C codon 389 in exon 9 and vitiligo susceptibility: a meta-analysis. J. Eur. Acad. Dermatol. Venereol. 25, 955\u2013958 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR52","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.freeradbiomed.2013.08.189","volume":"65","author":"NC Laddha","year":"2013","unstructured":"Laddha, N. C., Dwivedi, M., Gani, A. R., Shajil, E. M. & Begum, R. Involvement of superoxide dismutase isoenzymes and their genetic variants in progression of and higher susceptibility to vitiligo. Free Radic. Biol. Med. 65, 1110\u20131125 (2013).","journal-title":"Free Radic. Biol. Med."},{"key":"670_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1755-148X.2009.00610.x","volume":"22","author":"JD Simon","year":"2009","unstructured":"Simon, J. D., Peles, D., Wakamatsu, K. & Ito, S. Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function. Pigment Cell Melanoma Res. 22, 563\u2013579 (2009).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jcp.22027","volume":"223","author":"ML Dell\u2019Anna","year":"2010","unstructured":"Dell\u2019Anna, M. L. et al. Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. J. Cell. Physiol. 223, 187\u2013193 (2010).","journal-title":"J. Cell. Physiol."},{"key":"670_CR55","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.3390\/jcm12185861","volume":"12","author":"A Kassab","year":"2023","unstructured":"Kassab, A. et al. Serum inflammatory and oxidative stress markers in patients with vitiligo. J. Clin. Med. 12, 5861 (2023).","journal-title":"J. Clin. Med."},{"key":"670_CR56","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/1523-1747.ep12492612","volume":"97","author":"KU Schallreuter","year":"1991","unstructured":"Schallreuter, K. U., Wood, J. M. & Berger, J. Low catalase levels in the epidermis of patients with vitiligo. J. Investig. Dermatol 97, 1081\u20131085 (1991).","journal-title":"J. Investig. Dermatol"},{"key":"670_CR57","doi-asserted-by":"publisher","first-page":"8498472","DOI":"10.1155\/2022\/8498472","volume":"2022","author":"Y Xuan","year":"2022","unstructured":"Xuan, Y., Yang, Y., Xiang, L. & Zhang, C. The role of oxidative stress in the pathogenesis of vitiligo: a culprit for melanocyte death. Oxid. Med. Cell. Longev. 2022, 8498472 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"670_CR58","doi-asserted-by":"publisher","first-page":"1546836","DOI":"10.3389\/fphar.2025.1546836","volume":"16","author":"A Paganelli","year":"2025","unstructured":"Paganelli, A., Papaccio, F., Picardo, M. & Bellei, B. Metabolic anomalies in vitiligo: a new frontier for drug repurposing strategies. Front. Pharmacol. 16, 1546836 (2025).","journal-title":"Front. Pharmacol."},{"key":"670_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11056-9","volume":"7","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. T cells display mitochondria hyperpolarization in human type 1 diabetes. Sci. Rep. 7, 10835 (2017).","journal-title":"Sci. Rep."},{"key":"670_CR60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/1529-0131(200201)46:1<175::AID-ART10015>3.0.CO;2-H","volume":"46","author":"P Gergely","year":"2002","unstructured":"Gergely, P. et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 46, 175\u2013190 (2002).","journal-title":"Arthritis Rheum."},{"key":"670_CR61","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.it.2004.05.001","volume":"25","author":"A Perl","year":"2004","unstructured":"Perl, A., Gergely, P., Nagy, G., Koncz, A. & Banki, K. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol. 25, 360\u2013367 (2004).","journal-title":"Trends Immunol."},{"key":"670_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1810","volume":"14","author":"ACB Sant\u2019Anna-Silva","year":"2024","unstructured":"Sant\u2019Anna-Silva, A. C. B. et al. Vitiligo auto-immune response upon oxidative stress-related mitochondrial DNA release opens up new therapeutic strategies. Clin. Transl. Med. 14, e1810 (2024).","journal-title":"Clin. Transl. Med."},{"key":"670_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdermsci.2024.12.002","volume":"117","author":"X Xu","year":"2025","unstructured":"Xu, X., Lu, X., Zheng, Y., Xie, Y. & Lai, W. Cytosolic mtDNA-cGAS-STING axis mediates melanocytes pyroptosis to promote CD8+ T-cell activation in vitiligo. J. Dermatol. Sci. 117, 61\u201370 (2025).","journal-title":"J. Dermatol. Sci."},{"key":"670_CR64","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.humimm.2014.09.003","volume":"75","author":"HA Al-Shobaili","year":"2014","unstructured":"Al-Shobaili, H. A. & Rasheed, Z. Mitochondrial DNA acquires immunogenicity on exposure to nitrosative stress in patients with vitiligo. Hum. Immunol. 75, 1053\u20131061 (2014).","journal-title":"Hum. Immunol."},{"key":"670_CR65","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.7150\/thno.30398","volume":"9","author":"X Yi","year":"2019","unstructured":"Yi, X. et al. SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo. Theranostics 9, 1614\u20131633 (2019).","journal-title":"Theranostics"},{"key":"670_CR66","doi-asserted-by":"publisher","first-page":"7617839","DOI":"10.1155\/2021\/7617839","volume":"2021","author":"J Tian","year":"2021","unstructured":"Tian, J. et al. The formation of melanocyte apoptotic bodies in vitiligo and the relocation of vitiligo autoantigens under oxidative stress. Oxid. Med. Cell. Longev. 2021, 7617839 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"670_CR67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jid.2023.08.006","volume":"144","author":"EJ Lee","year":"2024","unstructured":"Lee, E. J. et al. ISG15\u2013USP18 dysregulation by oxidative stress promotes IFN-\u03b3 secretion from CD8+ T cells in vitiligo. J. Investig. Dermatol. 144, 273\u2013283.e11 (2024).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR68","volume":"5","author":"N Boukhedouni","year":"2020","unstructured":"Boukhedouni, N. et al. Type-1 cytokines regulate matrix metalloprotease-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight 5, e133772 (2020).","journal-title":"JCI Insight"},{"key":"670_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059782","volume":"8","author":"B Bellei","year":"2013","unstructured":"Bellei, B. et al. Vitiligo: a possible model of degenerative diseases. PLoS ONE\u00a08, e59782 (2013).","journal-title":"PLoS ONE"},{"key":"670_CR70","doi-asserted-by":"publisher","first-page":"111779","DOI":"10.1016\/j.mad.2023.111779","volume":"211","author":"B-Q Dong","year":"2023","unstructured":"Dong, B.-Q. et al. Acceleration of melanocyte senescence by the proinflammatory cytokines IFN\u03b3 and TNF\u03b1 impairs the repigmentation response of vitiligo patients to narrowband ultraviolet B (NBUVB) phototherapy. Mech. Ageing Dev. 211, 111779 (2023).","journal-title":"Mech. Ageing Dev."},{"key":"670_CR71","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/exd.13858","volume":"28","author":"V Delmas","year":"2019","unstructured":"Delmas, V. & Larue, L. Molecular and cellular basis of depigmentation in vitiligo patients. Exp. Dermatol. 28, 662\u2013666 (2019).","journal-title":"Exp. Dermatol."},{"key":"670_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2022.01.002","author":"X Hou","year":"2022","unstructured":"Hou, X. et al. The involvement of ERK1\/2 and p38 MAPK in the premature senescence of melanocytes induced by H2O2 through a p53-independent p21 pathway. J. Dermatol. Sci. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.01.002 (2022).","journal-title":"J. Dermatol. Sci."},{"key":"670_CR73","volume":"17","author":"V Salazar-Formoso","year":"2025","unstructured":"Salazar-Formoso, V. & Morales-S\u00e1nchez, M. A. Efficacy of superoxide dismutase in the treatment of vitiligo: a systematic review. Cureus 17, e88335 (2025).","journal-title":"Cureus"},{"key":"670_CR74","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40291-023-00672-z","volume":"27","author":"A Bia\u0142czyk","year":"2023","unstructured":"Bia\u0142czyk, A., We\u0142niak, A., Kami\u0144ska, B. & Czajkowski, R. Oxidative stress and potential antioxidant therapies in vitiligo: a narrative review. Mol. Diagn. Ther. 27, 723\u2013739 (2023).","journal-title":"Mol. Diagn. Ther."},{"key":"670_CR75","doi-asserted-by":"publisher","first-page":"116811","DOI":"10.1016\/j.bcp.2025.116811","volume":"234","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. MitoQ alleviates H2O2-induced mitochondrial dysfunction in keratinocytes through the Nrf2\/PINK1 pathway. Biochem. Pharmacol. 234, 116811 (2025).","journal-title":"Biochem. Pharmacol."},{"key":"670_CR76","doi-asserted-by":"publisher","first-page":"119995","DOI":"10.1016\/j.bbamcr.2025.119995","volume":"1872","author":"R Xiong","year":"2025","unstructured":"Xiong, R. et al. MitoQ for vitiligo by mitigating PARP1 translocation aberrations: network pharmacology and experimental validation. Biochim. Biophys. Acta Mol. Cell Res. 1872, 119995 (2025).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"670_CR77","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1016\/j.jid.2019.03.1148","volume":"139","author":"T Cui","year":"2019","unstructured":"Cui, T. et al. Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo. J. Investig. Dermatol. 139, 2174\u20132184.e4 (2019).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR78","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/bjd.15151","volume":"176","author":"JY Kim","year":"2017","unstructured":"Kim, J. Y., Lee, E. J., Seo, J. & Oh, S. H. Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo. Br. J. Dermatol. 176, 1558\u20131568 (2017).","journal-title":"Br. J. Dermatol."},{"key":"670_CR79","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","volume":"138","author":"SW Henning","year":"2018","unstructured":"Henning, S. W. et al. HSP70iQ435A-encoding DNA repigments vitiligo lesions in sinclair swine. J. Investig. Dermatol. 138, 2531\u20132539 (2018).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR80","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bjd.15550","volume":"177","author":"C Jacquemin","year":"2017","unstructured":"Jacquemin, C. et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. Br. J. Dermatol. 177, 1367\u20131375 (2017).","journal-title":"Br. J. Dermatol."},{"key":"670_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09963-8","volume":"10","author":"MK Tulic","year":"2019","unstructured":"Tulic, M. K. et al. Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo. Nat. Commun. 10, 2178 (2019).","journal-title":"Nat. Commun."},{"key":"670_CR82","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaci.2019.10.036","volume":"145","author":"S Li","year":"2020","unstructured":"Li, S. et al. Activated NLR family pyrin domain-containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo. J. Allergy Clin. Immunol. 145, 632\u2013645 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"670_CR83","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jid.2016.12.028","volume":"137","author":"AF Rezk","year":"2017","unstructured":"Rezk, A. F. et al. Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression. J. Investig. Dermatol. 137, 1126\u20131134 (2017).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","volume":"46","author":"S Cheuk","year":"2017","unstructured":"Cheuk, S. et al. CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. Immunity 46, 287\u2013300 (2017).","journal-title":"Immunity"},{"key":"670_CR85","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","volume":"138","author":"K Boniface","year":"2018","unstructured":"Boniface, K. et al. Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J. Investig. Dermatol. 138, 355\u2013364 (2018).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR86","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jid.2019.11.013","volume":"140","author":"C Jacquemin","year":"2020","unstructured":"Jacquemin, C. et al. NKG2D defines a subset of skin effector memory CD8 T cells with proinflammatory functions in vitiligo. J. Investig. Dermatol. 140, 1143\u20131153.e5 (2020).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","volume":"10","author":"JM Richmond","year":"2018","unstructured":"Richmond, J. M. et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci. Transl. Med. 10, eaam7710 (2018).","journal-title":"Sci. Transl. Med."},{"key":"670_CR88","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6, 223ra23 (2014).","journal-title":"Sci. Transl. Med."},{"key":"670_CR89","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn, J. G. et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Investig. Dermatol. 129, 2220\u20132232 (2009).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR90","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","volume":"601","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. Anatomically distinct fibroblast subsets determine skin autoimmune patterns. Nature 601, 118\u2013124 (2022).","journal-title":"Nature"},{"key":"670_CR91","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","volume":"116","author":"KS Lang","year":"2001","unstructured":"Lang, K. S. et al. HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against melanA\/MART1. J. Investig. Dermatol. 116, 891\u2013897 (2001).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR92","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","volume":"188","author":"GS Ogg","year":"1998","unstructured":"Ogg, G. S., Dunbar, P. R., Romero, P., Chen, J.-L. & Cerundolo, V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188, 1203\u20131208 (1998).","journal-title":"J. Exp. Med."},{"key":"670_CR93","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","volume":"117","author":"B Palermo","year":"2001","unstructured":"Palermo, B. et al. Specific cytotoxic T lymphocyte responses against melan-A\/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J. Investig. Dermatol. 117, 326\u2013332 (2001).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR94","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","volume":"143","author":"T Czarnowicki","year":"2018","unstructured":"Czarnowicki, T. et al. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J. Allergy Clin. Immunol. 143, 2095\u20132107 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"670_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf041","author":"J Gay-Mimbrera","year":"2025","unstructured":"Gay-Mimbrera, J. et al. Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in nonsegmental vitiligo. Br. J. Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljaf041 (2025).","journal-title":"Br. J. Dermatol."},{"key":"670_CR96","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/bjd.18902","volume":"183","author":"C Martins","year":"2020","unstructured":"Martins, C. et al. Phenotype and function of circulating memory T cells in human vitiligo. Br. J. Dermatol. 183, 899\u2013908 (2020).","journal-title":"Br. J. Dermatol."},{"key":"670_CR97","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","volume":"142","author":"C Martins","year":"2022","unstructured":"Martins, C. et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through JAK signaling. J. Investig. Dermatol. 142, 1194\u20131205.e7 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR98","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaci.2016.10.013","volume":"140","author":"S Li","year":"2017","unstructured":"Li, S. et al. Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes. J. Allergy Clin. Immunol. 140, 177\u2013189.e9 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"670_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.06.002","author":"PM Brunner","year":"2025","unstructured":"Brunner, P. M. et al. Transcriptomic profiling of vitiligo patients shows polar immune dysregulation in involved and uninvolved skin. J. Allergy Clin. Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2025.06.002 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"670_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.04.027","author":"V Azzolino","year":"2020","unstructured":"Azzolino, V. et al. JAK inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2020.04.027 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR101","doi-asserted-by":"publisher","first-page":"6952299","DOI":"10.1155\/2022\/6952299","volume":"2022","author":"PS Giri","year":"2022","unstructured":"Giri, P. S., Mistry, J. & Dwivedi, M. Meta-analysis of alterations in regulatory T cells\u2019 frequency and suppressive capacity in patients with vitiligo. J. Immunol. Res. 2022, 6952299 (2022).","journal-title":"J. Immunol. Res."},{"key":"670_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14982","volume":"33","author":"F Shah","year":"2024","unstructured":"Shah, F., Giri, P. S., Bharti, A. H. & Dwivedi, M. Compromised melanocyte survival due to decreased suppression of CD4+ & CD8+ resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients. Exp. Dermatol. 33, e14982 (2024).","journal-title":"Exp. Dermatol."},{"key":"670_CR103","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.jaut.2022.102859","volume":"131","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Th1-like Treg in vitiligo: an incompetent regulator in immune tolerance. J. Autoimmun. 131, 102859 (2022).","journal-title":"J. Autoimmun."},{"key":"670_CR104","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jid.2022.05.1090","volume":"142","author":"KI Essien","year":"2022","unstructured":"Essien, K. I., Katz, E. L., Strassner, J. P. & Harris, J. E. Regulatory T cells require CCR6 for skin migration and local suppression of vitiligo. J. Investig. Dermatol. 142, 3158\u20133166.e7 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR105","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41586-023-06217-y","volume":"619","author":"M Damo","year":"2023","unstructured":"Damo, M. et al. PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. Nature 619, 151\u2013159 (2023).","journal-title":"Nature"},{"key":"670_CR106","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/exd.14500","volume":"31","author":"M Willemsen","year":"2022","unstructured":"Willemsen, M. et al. IFN-\u03b3-induced PD-L1 expression on human melanocytes is impaired in vitiligo. Exp. Dermatol. 31, 556\u2013566 (2022).","journal-title":"Exp. Dermatol."},{"key":"670_CR107","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdin.2021.09.002","volume":"5","author":"L Dousset","year":"2021","unstructured":"Dousset, L. et al. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti\u2013programmed cell death-1 therapies for melanoma: a cross-sectional study. JAAD Int. 5, 112\u2013120 (2021).","journal-title":"JAAD Int."},{"key":"670_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19407-w","volume":"8","author":"X Miao","year":"2018","unstructured":"Miao, X. et al. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Sci. Rep. 8, 1605 (2018).","journal-title":"Sci. Rep."},{"key":"670_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.017","author":"L Migayron","year":"2023","unstructured":"Migayron, L., Merhi, R., Seneschal, J. & Boniface, K. Resident memory T cells in non-lesional skin and healed lesions of patients with chronic inflammatory diseases: appearances can be deceptive. J. Allergy Clin. Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.017 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"670_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.01.033","author":"R Merhi","year":"2025","unstructured":"Merhi, R., Boniface, K. & Seneschal, J. Unveiling the unseen: exploring cellular dynamics in nonlesional vitiligo skin. J. Investig. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2025.01.033 (2025).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.10.598","author":"MK Tulic","year":"2024","unstructured":"Tulic, M. K. et al. Focusing on the dark side of the moon: involvement of the nonlesional skin in vitiligo. J. Investig. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2024.10.598 (2024).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR112","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/jid.2015.25","volume":"135","author":"RY Wagner","year":"2015","unstructured":"Wagner, R. Y. et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J. Investig. Dermatol. 135, 1810\u20131819 (2015).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13961-5","volume":"7","author":"ML Dell\u2019Anna","year":"2017","unstructured":"Dell\u2019Anna, M. L. et al. Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. Sci. Rep. 7, 13663 (2017).","journal-title":"Sci. Rep."},{"key":"670_CR114","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1074\/jbc.M109.047027","volume":"285","author":"H-L Chan","year":"2010","unstructured":"Chan, H.-L. et al. Major role of epidermal growth factor receptor and src kinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells. J. Biol. Chem. 285, 4307\u20134318 (2010).","journal-title":"J. Biol. Chem."},{"key":"670_CR115","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn9299","volume":"8","author":"D Kovacs","year":"2022","unstructured":"Kovacs, D. et al. Altered epidermal proliferation, differentiation, and lipid composition: novel key elements in the vitiligo puzzle. Sci. Adv. 8, eabn9299 (2022).","journal-title":"Sci. Adv."},{"key":"670_CR116","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jid.2017.06.033","volume":"138","author":"D Kovacs","year":"2018","unstructured":"Kovacs, D. et al. Vitiligo skin: exploring the dermal compartment. J. Investig. Dermatol. 138, 394\u2013404 (2018).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8995","volume":"13","author":"KJ Gellatly","year":"2021","unstructured":"Gellatly, K. J. et al. scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function. Sci. Transl. Med. 13, eabd8995 (2021).","journal-title":"Sci. Transl. Med."},{"key":"670_CR118","doi-asserted-by":"publisher","first-page":"9860","DOI":"10.1038\/s41598-017-10253-w","volume":"7","author":"A Singh","year":"2017","unstructured":"Singh, A. et al. Mapping architectural and transcriptional alterations in non-lesional and lesional epidermis in vitiligo. Sci. Rep. 7, 9860 (2017).","journal-title":"Sci. Rep."},{"key":"670_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051040","volume":"7","author":"R Yu","year":"2012","unstructured":"Yu, R. et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS ONE\u00a07, e51040 (2012).","journal-title":"PLoS ONE"},{"key":"670_CR120","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.det.2016.11.015","volume":"35","author":"SA Birlea","year":"2017","unstructured":"Birlea, S. A., Goldstein, N. B. & Norris, D. A. Repigmentation through melanocyte regeneration in vitiligo. Dermatol. Clin. 35, 205\u2013218 (2017).","journal-title":"Dermatol. Clin."},{"key":"670_CR121","doi-asserted-by":"publisher","first-page":"1397067","DOI":"10.3389\/fphys.2024.1397067","volume":"15","author":"A Kiselev","year":"2024","unstructured":"Kiselev, A. & Park, S. Immune niches for hair follicle development and homeostasis. Front. Physiol. 15, 1397067 (2024).","journal-title":"Front. Physiol."},{"key":"670_CR122","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jid.2017.09.040","volume":"138","author":"NB Goldstein","year":"2018","unstructured":"Goldstein, N. B. et al. Repigmentation of human vitiligo skin by NBUVB is controlled by transcription of GLI1 and activation of the \u03b2-catenin pathway in the hair follicle bulge stem cells. J. Invest. Dermatol. 138, 657\u2013668 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR123","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/jid.2015.335","volume":"135","author":"C Regazzetti","year":"2015","unstructured":"Regazzetti, C. et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. J. Invest. Dermatol. 135, 3105\u20133114 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR124","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jid.2020.07.016","volume":"141","author":"NB Goldstein","year":"2020","unstructured":"Goldstein, N. B. et al. Melanocyte precursors in the hair follicle bulge of repigmented vitiligo skin are controlled by RHO-GTPase, KCTD10 and CTNNB1 signaling. J. Invest. Dermatol. 141, 638\u2013647.e13 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR125","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamadermatol.2020.5756","volume":"157","author":"HJ Ju","year":"2021","unstructured":"Ju, H. J. et al. Surgical interventions for patients with vitiligo. JAMA Dermatol. 157, 307\u2013316 (2021).","journal-title":"JAMA Dermatol."},{"key":"670_CR126","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1111\/jdv.15604","volume":"33","author":"N van Geel","year":"2019","unstructured":"van Geel, N. et al. Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 33, 1667\u20131675 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR127","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2016.09.034","volume":"76","author":"N van Geel","year":"2017","unstructured":"van Geel, N. et al. Development and validation of a patient-reported outcome measure in vitiligo: the self assessment vitiligo extent score (SA-VES). J. Am. Acad. Dermatol. 76, 464\u2013471 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR128","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70014","volume":"38","author":"J Duponselle","year":"2025","unstructured":"Duponselle, J. et al. Quality analysis of measurement properties of patient-reported outcome measures for vitiligo and of the studies assessing them: a systematic review. Pigment Cell Melanoma Res. 38, e70014 (2025).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR129","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/JID.2015.398","volume":"136","author":"C Salzes","year":"2016","unstructured":"Salzes, C. et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J. Investig. Dermatol. 136, 52\u201358 (2016).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR130","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/jcm14082548","volume":"14","author":"J Duponselle","year":"2025","unstructured":"Duponselle, J. et al. A quality analysis of the measurement properties of the clinician-reported outcome measures for vitiligo and of the studies assessing them: a systematic review. J. Clin. Med. 14, 2548 (2025).","journal-title":"J. Clin. Med."},{"key":"670_CR131","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1111\/jdv.19448","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel, N. et al. Clinician-reported outcome measures for the assessment of vitiligo: a scoping review. J. Eur. Acad. Dermatol. Venereol. 37, 2231\u20132242 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR132","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi, I. et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. Arch. Dermatol. 140, 677\u2013683 (2004).","journal-title":"Arch. Dermatol."},{"key":"670_CR133","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","volume":"136","author":"N van Geel","year":"2016","unstructured":"van Geel, N. et al. Development and validation of the vitiligo extent score (VES): an international collaborative initiative. J. Investig. Dermatol. 136, 978\u2013984 (2016).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR134","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2017.12.070","volume":"79","author":"N van Geel","year":"2018","unstructured":"van Geel, N. et al. The vitiligo extent score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. J. Am. Acad. Dermatol. 79, 369\u2013371 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR135","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20563","author":"R Speeckaert","year":"2025","unstructured":"Speeckaert, R. et al. Reliability of measurement instruments for vitiligo extent and their feasibility: a meta-analysis. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/jdv.20563 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR136","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bjd.18950","volume":"183","author":"N van Geel","year":"2020","unstructured":"van Geel, N. et al. Reliability and validity of the vitiligo signs of activity score (VSAS). Br. J. Dermatol. 183, 883\u2013890 (2020).","journal-title":"Br. J. Dermatol."},{"key":"670_CR137","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jdv.18134","volume":"36","author":"N van Geel","year":"2022","unstructured":"van Geel, N. et al. Assessing the dynamic changes in vitiligo: reliability and validity of the vitiligo disease activity score (VDAS) and vitiligo disease improvement score (VDIS). J. Eur. Acad. Dermatol. Venereol. 36, 1334\u20131341 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR138","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/pcmr.13056","volume":"35","author":"N van Geel","year":"2022","unstructured":"van Geel, N. et al. Image analysis systems to calculate the surface area of vitiligo lesions: a systematic review of measurement properties. Pigment Cell Melanoma Res. 35, 480\u2013494 (2022).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR139","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jid.2023.07.014","volume":"144","author":"D Hillmer","year":"2024","unstructured":"Hillmer, D. et al. Evaluation of facial vitiligo severity with a mixed clinical and artificial intelligence approach. J. Investig. Dermatol. 144, 351\u2013357.e4 (2024).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR140","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad304","author":"QMD Bertoud","year":"2023","unstructured":"Bertoud, Q. M. D. et al. Reliability and agreement testing of a new automated measurement method to determine extent of facial vitiligo using standardized UV images and a dedicated algorithm. Br. J. Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljad304 (2023).","journal-title":"Br. J. Dermatol."},{"key":"670_CR141","doi-asserted-by":"publisher","first-page":"1200963","DOI":"10.3389\/fmed.2023.1200963","volume":"10","author":"P Abdi","year":"2023","unstructured":"Abdi, P. et al. Non-invasive skin measurement methods and diagnostics for vitiligo: a systematic review. Front. Med. 10, 1200963 (2023).","journal-title":"Front. Med."},{"key":"670_CR142","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.det.2016.11.004","volume":"35","author":"B-K Goh","year":"2017","unstructured":"Goh, B.-K. & Pandya, A. G. Presentations, signs of activity, and differential diagnosis of vitiligo. Dermatol. Clin. 35, 135\u2013144 (2017).","journal-title":"Dermatol. Clin."},{"key":"670_CR143","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00403-023-02611-8","volume":"315","author":"NF Post","year":"2023","unstructured":"Post, N. F. et al. Expert opinion about laser and intense pulsed light (IPL)-induced leukoderma or vitiligo: a cross-sectional survey study. Arch. Dermatol. Res. 315, 2289\u20132294 (2023).","journal-title":"Arch. Dermatol. Res."},{"key":"670_CR144","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15167","volume":"33","author":"L Delbaere","year":"2024","unstructured":"Delbaere, L., Duponselle, J., Herbelet, S., Speeckaert, R. & van Geel, N. Predictive value of disease activity signs in vitiligo: an observational study. Exp. Dermatol. 33, e15167 (2024).","journal-title":"Exp. Dermatol."},{"key":"670_CR145","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamadermatol.2019.4483","volume":"156","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Association of clinical markers with disease progression in patients with vitiligo from China. JAMA Dermatol. 156, 288\u2013295 (2020).","journal-title":"JAMA Dermatol."},{"key":"670_CR146","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19450","author":"J Seneschal","year":"2023","unstructured":"Seneschal, J. et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force \u2014 part 2: specific treatment recommendations. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/jdv.19450 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR147","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bjd.21669","volume":"187","author":"V Goulden","year":"2022","unstructured":"Goulden, V. et al. British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022. Br. J. Dermatol. 187, 295\u2013308 (2022).","journal-title":"Br. J. Dermatol."},{"key":"670_CR148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues, M. et al. Current and emerging treatments for vitiligo. J. Am. Acad. Dermatol. 77, 17\u201329 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR149","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/bjd.20137","volume":"185","author":"J Shourick","year":"2021","unstructured":"Shourick, J. et al. Development of a shared decision-making tool in vitiligo: an international study. Br. J. Dermatol. 185, 787\u2013796 (2021).","journal-title":"Br. J. Dermatol."},{"key":"670_CR150","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15219","volume":"35","author":"SM Esmat","year":"2022","unstructured":"Esmat, S. M. et al. Early localized vitiligo, a medical emergency: long-term follow-up study. Dermatol. Ther. 35, e15219 (2022).","journal-title":"Dermatol. Ther."},{"key":"670_CR151","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1755-148X.2010.00703.x","volume":"23","author":"NAC van Geel","year":"2010","unstructured":"van Geel, N. A. C. et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 23, 375\u2013384 (2010).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR152","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1468-3083.2011.04215.x","volume":"26","author":"SM Esmat","year":"2012","unstructured":"Esmat, S. M. et al. Acral lesions of vitiligo: why are they resistant to photochemotherapy? J. Eur. Acad. Dermatol. Venereol. 26, 1097\u20131104 (2012).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR153","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou, V. et al. British association of dermatologists guidelines for the management of people with vitiligo 2021. Brit. J. Dermatol. 186, 18\u201329 (2022).","journal-title":"Brit. J. Dermatol."},{"key":"670_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","volume":"54","author":"UR Hengge","year":"2006","unstructured":"Hengge, U. R., Ruzicka, T., Schwartz, R. A. & Cork, M. J. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 54, 1\u201315 (2006).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR155","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jid.2020.12.028","volume":"141","author":"J Seneschal","year":"2021","unstructured":"Seneschal, J. et al. Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. J. Investig. Dermatol. 141, 1728\u20131734 (2021).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR156","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","volume":"155","author":"JH Lee","year":"2019","unstructured":"Lee, J. H. et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo. JAMA Dermatol. 155, 929\u2013938 (2019).","journal-title":"JAMA Dermatol."},{"key":"670_CR157","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin, D. et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N. Engl. J. Med. 387, 1445\u20131455 (2022).","journal-title":"N. Engl. J. Med."},{"key":"670_CR158","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20236","author":"T Passeron","year":"2024","unstructured":"Passeron, T. et al. Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/jdv.20236 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR159","unstructured":"Estebaranz, J. L. L. et al. P2983: Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo Through 2 Years in the TRuE-V Studies (European Academy of Dermatology and Venereology (EADV) Congress, 2024)."},{"key":"670_CR160","unstructured":"Rosmarin, D. et al. P2984: Characterizing Maintenance of Repigmentation in a Post Hoc Analysis of the TRuE-V Long-Term Extension Study of Ruxolitinib Cream in Vitiligo (European Academy of Dermatology and Venereology (EADV) Congress, 2024)."},{"key":"670_CR161","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bjd.17150","volume":"180","author":"A Tovar-Garza","year":"2019","unstructured":"Tovar-Garza, A., Hinojosa, J. A., Hynan, L. S. & Pandya, A. G. Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo. Br. J. Dermatol. 180, 193\u2013194 (2019).","journal-title":"Br. J. Dermatol."},{"key":"670_CR162","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice, J. B., White, A. G., Scarpati, L. M., Wan, G. & Nelson, W. W. Long-term systemic corticosteroid exposure: a systematic literature review. Clin. Ther. 39, 2216\u20132229 (2017).","journal-title":"Clin. Ther."},{"key":"670_CR163","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaad.2018.10.010","volume":"85","author":"HM Jung","year":"2021","unstructured":"Jung, H. M., Jung, Y. S., Lee, J. H., Kim, G. M. & Bae, J. M. Antioxidant supplements in combination with phototherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials. J. Am. Acad. Dermatol. 85, 506\u2013508 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR164","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/jdv.17331","volume":"35","author":"E Fontas","year":"2021","unstructured":"Fontas, E., Montaudi\u00e9, H. & Passeron, T. Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a 24-week prospective randomized placebo-controlled study. J. Eur. Acad. Dermatol. 35, 1725\u20131729 (2021).","journal-title":"J. Eur. Acad. Dermatol."},{"key":"670_CR165","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","volume":"153","author":"JM Bae","year":"2017","unstructured":"Bae, J. M. et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 153, 666 (2017).","journal-title":"JAMA Dermatol."},{"key":"670_CR166","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jid.2023.08.012","volume":"144","author":"A Rooker","year":"2024","unstructured":"Rooker, A., Ouwerkerk, W., Bekkenk, M. W., Luiten, R. M. & Bakker, W. J. The risk of keratinocyte cancer in vitiligo and the potential mechanisms involved. J. Investig. Dermatol. 144, 234\u2013242 (2024).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR167","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ced.15010","volume":"47","author":"Y-H Wu","year":"2022","unstructured":"Wu, Y.-H., Chou, C.-L. & Chang, H.-C. Risk of skin cancer after ultraviolet phototherapy in patients with vitiligo: a systematic review and meta-analysis. Clin. Exp. Dermatol. 47, 692\u2013699 (2022).","journal-title":"Clin. Exp. Dermatol."},{"key":"670_CR168","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","volume":"76","author":"TF Mohammad","year":"2017","unstructured":"Mohammad, T. F. et al. The vitiligo working group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J. Am. Acad. Dermatol. 76, 879\u2013888 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR169","doi-asserted-by":"publisher","first-page":"2514637","DOI":"10.1080\/09546634.2025.2514637","volume":"36","author":"T Tantivithiwate","year":"2025","unstructured":"Tantivithiwate, T. et al. Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study. J. Dermatol. Treat. 36, 2514637 (2025).","journal-title":"J. Dermatol. Treat."},{"key":"670_CR170","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/jlms.2017.22","volume":"8","author":"MMS Eldin","year":"2017","unstructured":"Eldin, M. M. S., Sami, N. A., Aly, D. G. & Hanafy, N. S. Comparison between (311\u2013312 nm) narrow band ultraviolet-B phototherapy and (308 nm) monochromatic excimer light phototherapy in treatment of vitiligo: a histopathological study. J. Lasers M\u00e9d. Sci. 8, 123\u2013127 (2017).","journal-title":"J. Lasers M\u00e9d. Sci."},{"key":"670_CR171","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-015-0164-2","volume":"17","author":"C Lopes","year":"2016","unstructured":"Lopes, C., Trevisani, V. F. M. & Melnik, T. Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: a systematic review with meta-analysis. Am. J. Clin. Dermatol. 17, 23\u201332 (2016).","journal-title":"Am. J. Clin. Dermatol."},{"key":"670_CR172","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/09546634.2014.991268","volume":"26","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J. Dermatol. Treat. 26, 347\u2013353 (2015).","journal-title":"J. Dermatol. Treat."},{"key":"670_CR173","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/phpp.12321","volume":"33","author":"TF Mohammad","year":"2017","unstructured":"Mohammad, T. F., Silpa-Archa, N., Griffith, J. L., Lim, H. W. & Hamzavi, I. H. Home phototherapy in vitiligo. Photodermatol. Photoimmunol. Photomed. 33, 241\u2013252 (2017).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"670_CR174","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/phpp.12766","volume":"38","author":"AZ Ashraf","year":"2022","unstructured":"Ashraf, A. Z., Azurdia, R. M. & Cohen, S. N. The effectiveness of home-based phototherapy for vitiligo: a systematic review of randomised controlled trials. Photodermatol. Photoimmunol. Photomed. 38, 409\u2013417 (2022).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"670_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.05.1093","author":"AG Pandya","year":"2022","unstructured":"Pandya, A. G. et al. Addition of narrow-band ultraviolet light B (UVB) phototherapy to ruxolitinib cream in patients with vitiligo. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2022.05.1093 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"670_CR176","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2024.5737","volume":"161","author":"J Seneschal","year":"2025","unstructured":"Seneschal, J. et al. Combination of baricitinib and phototherapy in adults with active vitiligo. JAMA Dermatol. 161, 375\u2013382 (2025).","journal-title":"JAMA Dermatol."},{"key":"670_CR177","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4103\/0378-6323.42905","volume":"74","author":"H Kar","year":"2008","unstructured":"Kar, H., Sabhnani, S. & Rath, N. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad \/ narrow band UVB phototherapy in progressive vitiligo. Indian J. Dermatol. Venereol. Leprol. 74, 357 (2008).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"670_CR178","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jaad.2018.06.016","volume":"79","author":"JM Bae","year":"2018","unstructured":"Bae, J. M., Lee, J. H., Kwon, H. S., Kim, J. & Kim, D. S. Motorized 0.8-mm micropunch grafting for refractory vitiligo: a retrospective study of 230 cases. J. Am. Acad. Dermatol. 79, 720\u2013727.e1 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR179","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1067\/mjd.2003.415","volume":"49","author":"S Gupta","year":"2003","unstructured":"Gupta, S. & Kumar, B. Epidermal grafting in vitiligo: Influence of age, site of lesion, and type of disease on outcome. J. Am. Acad. Dermatol. 49, 99\u2013104 (2003).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR180","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/0190-9622(95)91329-7","volume":"32","author":"SK Hann","year":"1995","unstructured":"Hann, S. K., Im, S., Bong, H. W. & Park, Y.-K. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J. Am. Acad. Dermatol. 32, 943\u2013948 (1995).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR181","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2230.2011.04065.x","volume":"36","author":"K Sahni","year":"2011","unstructured":"Sahni, K., Parsad, D. & Kanwar, A. J. Noncultured epidermal suspension transplantation for the treatment of stable vitiligo in children and adolescents. Clin. Exp. Dermatol. 36, 607\u2013612 (2011).","journal-title":"Clin. Exp. Dermatol."},{"key":"670_CR182","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/archderm.140.10.1203","volume":"140","author":"N van Geel","year":"2004","unstructured":"van Geel, N. et al. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch. Dermatol. 140, 1203\u20131208 (2004).","journal-title":"Arch. Dermatol."},{"key":"670_CR183","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/stcltm\/szae009","volume":"13","author":"J Li","year":"2024","unstructured":"Li, J. et al. The treatment of refractory vitiligo with autologous cultured epithelium grafting: a real-world retrospective cohort study. Stem Cell Transl. Med. 13, 415\u2013424 (2024).","journal-title":"Stem Cell Transl. Med."},{"key":"670_CR184","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/jdv.14950","volume":"32","author":"JE Lommerts","year":"2018","unstructured":"Lommerts, J. E., Uitentuis, S. E., Bekkenk, M. W., de Rie, M. A. & Wolkerstorfer, A. The role of phototherapy in the surgical treatment of vitiligo: a systematic review. J. Eur. Acad. Dermatol. Venereol. 32, 1427\u20131435 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR185","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","volume":"56","author":"E Nicolaidou","year":"2007","unstructured":"Nicolaidou, E., Antoniou, C., Stratigos, A. J., Stefanaki, C. & Katsambas, A. D. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J. Am. Acad. Dermatol. 56, 274\u2013278 (2007).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR186","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"M Cavali\u00e9","year":"2015","unstructured":"Cavali\u00e9, M. et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J. Investig. Dermatol. 135, 970\u2013974 (2015).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568447","volume":"11","author":"R Speeckaert","year":"2020","unstructured":"Speeckaert, R. et al. Autoimmunity in segmental vitiligo. Front. Immunol. 11, 568447 (2020).","journal-title":"Front. Immunol."},{"key":"670_CR188","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/ijd.17627","volume":"64","author":"X Lin","year":"2025","unstructured":"Lin, X., Meng, X. & Lin, J. Segmental vitiligo: autoimmune pathogenesis, neuronal mechanisms, and somatic mosaicism. Int. J. Dermatol. 64, 490\u2013498 (2025).","journal-title":"Int. J. Dermatol."},{"key":"670_CR189","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","volume":"69","author":"E Lilly","year":"2013","unstructured":"Lilly, E. et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J. Am. Acad. Dermatol. 69, e11\u2013e18 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.008","author":"K Ezzedine","year":"2019","unstructured":"Ezzedine, K. et al. Cross cultural validation of a short-form of the Vitiligo Impact Patient Scale (VIPs). J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.008 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR191","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau, K. et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo. JAMA Dermatol. 159, 1124\u20131128 (2023).","journal-title":"JAMA Dermatol."},{"key":"670_CR192","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s13555-025-01412-3","volume":"15","author":"P Grimes","year":"2025","unstructured":"Grimes, P. et al. Mental health and psychosocial burden among patients with skin of color living with vitiligo: findings from the global valiant study. Dermatol. Ther. 15, 1931\u20131939 (2025).","journal-title":"Dermatol. Ther."},{"key":"670_CR193","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s13555-025-01451-w","volume":"15","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine, K. et al. Exploring vitiligo history and mental health burden among people within EU5 countries: findings from the global valiant study. Dermatol. Ther. 15, 2439\u20132453 (2025).","journal-title":"Dermatol. Ther."},{"key":"670_CR194","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/12034754241269200","volume":"28","author":"T Yodtraiseevirat","year":"2024","unstructured":"Yodtraiseevirat, T. et al. Clinical and psychological implications of genital vitiligo in a Thai population. J. Cutan. Med. Surg. 28, 547\u2013553 (2024).","journal-title":"J. Cutan. Med. Surg."},{"key":"670_CR195","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1402a75","volume":"14","author":"G Awal","year":"2024","unstructured":"Awal, G., Kaur, N., Singh, G. & Sharma, N. Impact of vitiligo on quality of life in patients of skin of color and its correlation with clinical severity assessment scores utilizing disease specific scores: a cross-sectional study. Dermatol. Pr. Concept. 14, e2024075 (2024).","journal-title":"Dermatol. Pr. Concept."},{"key":"670_CR196","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae020","author":"A Fakih","year":"2023","unstructured":"Fakih, A. et al. Stigma in vitiligo: associated factors and severity strata of the PUSH-D score. Br. J. Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljae020 (2023).","journal-title":"Br. J. Dermatol."},{"key":"670_CR197","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1440-172X.2012.02047.x","volume":"18","author":"MF Chan","year":"2012","unstructured":"Chan, M. F. & Chua, T. L. The effectiveness of therapeutic interventions on quality of life for vitiligo patients: a systematic review. Int. J. Nurs. Pr. 18, 396\u2013405 (2012).","journal-title":"Int. J. Nurs. Pr."},{"key":"670_CR198","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo, M. et al. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J. Eur. Acad. Dermatol. Venereol. 36, 1507\u20131523 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR199","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine, K. et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J. Am. Acad. Dermatol. 88, 395\u2013403 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR200","doi-asserted-by":"publisher","first-page":"102655","DOI":"10.1016\/j.eclinm.2024.102655","volume":"73","author":"T Passeron","year":"2024","unstructured":"Passeron, T. et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. eClinicalMedicine 73, 102655 (2024).","journal-title":"eClinicalMedicine"},{"key":"670_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.027","author":"AG Pandya","year":"2025","unstructured":"Pandya, A. G. et al. Efficacy and safety of the oral janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.027 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR202","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"HW Lim","year":"2015","unstructured":"Lim, H. W. et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 151, 42\u201350 (2015).","journal-title":"JAMA Dermatol."},{"key":"670_CR203","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamadermatol.2014.4848","volume":"151","author":"T Passeron","year":"2015","unstructured":"Passeron, T. Indications and limitations of afamelanotide for treating vitiligo. JAMA Dermatol. 151, 349\u2013350 (2015).","journal-title":"JAMA Dermatol."},{"key":"670_CR204","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17982","author":"M da Costa Pereira Cestari","year":"2025","unstructured":"da Costa Pereira Cestari, M., Tovo, R. F. & Bueno, D. F. MSC-derived secretome and exosomes in dermatology: mechanisms, therapeutic opportunities, and scientific challenges \u2014 a narrative review. Int. J. Dermatol. https:\/\/doi.org\/10.1111\/ijd.17982 (2025).","journal-title":"Int. J. Dermatol."},{"key":"670_CR205","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.coi.2022.102266","volume":"80","author":"FW Miller","year":"2023","unstructured":"Miller, F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr. Opin. Immunol. 80, 102266 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"670_CR206","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/sj.jid.5701233","volume":"128","author":"GS LaBerge","year":"2008","unstructured":"LaBerge, G. S., Bennett, D. C., Fain, P. R. & Spritz, R. A. PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. J. Investig. Dermatol. 128, 1757\u20131762 (2008).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR207","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/jid.2009.273","volume":"130","author":"Y Jin","year":"2010","unstructured":"Jin, Y., Riccardi, S. L., Gowan, K., Fain, P. R. & Spritz, R. A. Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1). J. Investig. Dermatol. 130, 774\u2013783 (2010).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR208","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","volume":"362","author":"Y Jin","year":"2010","unstructured":"Jin, Y. et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. Engl. J. Med. 362, 1686\u20131697 (2010).","journal-title":"N. Engl. J. Med."},{"key":"670_CR209","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jid.2016.09.021","volume":"137","author":"Y Jin","year":"2017","unstructured":"Jin, Y., Andersen, G. H. L., Santorico, S. A. & Spritz, R. A. Multiple functional variants of IFIH1, a gene involved in triggering innate immune responses, protect against vitiligo. J. Investig. Dermatol 137, 522\u2013524 (2017).","journal-title":"J. Investig. Dermatol"},{"key":"670_CR210","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ng.2272","volume":"44","author":"Y Jin","year":"2012","unstructured":"Jin, Y. et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat. Genet. 44, 676\u2013680 (2012).","journal-title":"Nat. Genet."},{"key":"670_CR211","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1755-148X.2009.00543.x","volume":"22","author":"SA Birlea","year":"2009","unstructured":"Birlea, S. A., LaBerge, G. S., Procopciuc, L. M., Fain, P. R. & Spritz, R. A. CTLA4 and generalized vitiligo: two genetic association studies and a meta-analysis of published data. Pigment Cell Melanoma Res. 22, 230\u2013234 (2009).","journal-title":"Pigment Cell Melanoma Res."},{"key":"670_CR212","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/jid.2010.337","volume":"131","author":"SA Birlea","year":"2011","unstructured":"Birlea, S. A. et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J. Investig. Dermatol. 131, 371\u2013381 (2011).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR213","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/ng.602","volume":"42","author":"Y Jin","year":"2010","unstructured":"Jin, Y. et al. Common variants in FOXP1 are associated with generalized vitiligo. Nat. Genet. 42, 576\u2013578 (2010).","journal-title":"Nat. Genet."},{"key":"670_CR214","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/sj.jid.5700953","volume":"127","author":"Y Jin","year":"2007","unstructured":"Jin, Y., Birlea, S. A., Fain, P. R. & Spritz, R. A. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J. Investig. Dermatol. 127, 2558\u20132562 (2007).","journal-title":"J. Investig. Dermatol."},{"key":"670_CR215","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1073\/pnas.1222808110","volume":"110","author":"CB Levandowski","year":"2013","unstructured":"Levandowski, C. B. et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1\u03b2 processing via the NLRP1 inflammasome. Proc. Natl Acad. Sci. USA 110, 2952\u20132956 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"670_CR216","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1684\/ejd.2018.3449","volume":"28","author":"K-C Fan","year":"2018","unstructured":"Fan, K.-C., Yang, T.-H. & Huang, Y.-C. Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur. J. Dermatol. 28, 750\u2013763 (2018).","journal-title":"Eur. J. Dermatol."},{"key":"670_CR217","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","volume":"74","author":"L Gill","year":"2016","unstructured":"Gill, L. et al. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J. Am. Acad. Dermatol. 74, 295\u2013302 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR218","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s00403-024-02965-7","volume":"316","author":"NT Cohen","year":"2024","unstructured":"Cohen, N. T., Schonmann, Y. & Kridin, K. A bidirectional autoimmune cluster between vitiligo and rheumatoid arthritis: a large-scale population-based study. Arch. Dermatol. Res. 316, 366 (2024).","journal-title":"Arch. Dermatol. Res."},{"key":"670_CR219","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","volume":"82","author":"A Hadi","year":"2020","unstructured":"Hadi, A., Wang, J. F., Uppal, P., Penn, L. A. & Elbuluk, N. Comorbid diseases of vitiligo: a 10-year cross-sectional retrospective study of an urban US population. J. Am. Acad. Dermatol. 82, 628\u2013633 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"670_CR220","doi-asserted-by":"publisher","first-page":"1072837","DOI":"10.3389\/fmed.2023.1072837","volume":"10","author":"Z Hu","year":"2023","unstructured":"Hu, Z. & Wang, T. Beyond skin white spots: vitiligo and associated comorbidities. Front. Med. 10, 1072837 (2023).","journal-title":"Front. Med."},{"key":"670_CR221","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/jdv.12870","volume":"29","author":"YT Chen","year":"2015","unstructured":"Chen, Y. T. et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J. Eur. Acad. Dermatol. Venereol. 29, 1362\u20131369 (2015).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"670_CR222","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamadermatol.2013.4228","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg, J. I. & Silverberg, N. B. Association between vitiligo and atopic disorders: a pilot study. JAMA Dermatol. 149, 963 (2013).","journal-title":"JAMA Dermatol."},{"key":"670_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2649-z","volume":"11","author":"A Sreedhar","year":"2020","unstructured":"Sreedhar, A., Aguilera-Aguirre, L. & Singh, K. K. Mitochondria in skin health, aging, and disease. Cell Death Dis. 11, 444 (2020).","journal-title":"Cell Death Dis."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00670-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:02:24Z","timestamp":1764835344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00670-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":223,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1038\/s41572-025-00670-x","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"5 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. received grants and\/or honoraria from AbbVie, Bristol Myers Squibb, Calypso Biotech, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, Sun Pharmaceuticals, and Viela Bio and has a patent on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and on a 3D model of a depigmenting disorder. N.v.G. received grants, is a consultant and\/or is an investigator for AbbVie, Incyte, Merck\/MSD, Pfizer, Bristol Myers Squibb, Idorsia and Novartis; she was involved in the development of several measurement instruments for vitiligo. K.E. is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi and Viela Bio. K.B. has received grants and\/or honoraria from Calypso Biotech, LEO Pharma, Pfizer, Pierre Fabre, Sanofi, Silab, Almirall, and AnaptysBio and has a patent on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and on a 3D model of a depigmenting disorder. T.P. has received grants and\/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme\/Sanofi, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB and Vyne Therapeutics, is the cofounder of NIKAIA Pharmaceuticals, and has patents on WNT agonists and GSK3\u03b2 antagonists for repigmentation of vitiligo and on the use of CXCR3B blockers in vitiligo. J.E.H. has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme\/Sanofi, Janssen, Pfizer, Rheos Medicines, Sun Pharma, TeVido BioDevices, The Expert Institute, Third Rock Ventures and Villaris Therapeutics, has served as an investigator for Aclaris Therapeutics, Celgene, Dermira, EMD Serono, Genzyme\/Sanofi, Incyte Corporation, LEO Pharma, Pfizer, Rheos Medicines, Stiefel\/GlaxoSmithKline, Sun Pharma, TeVido BioDevices and Villaris Therapeutics, holds equity in Aldena Therapeutics, NIRA Biosciences, Rheos Medicines, TeVido BioDevices and Villaris Therapeutics, is a scientific founder of Aldena Therapeutics, NIRA Biosciences and Villaris Therapeutics, and has patents pending for IL-15 blockade for the treatment of vitiligo, JAK inhibition with light therapy for vitiligo, and anti-human CXCR3 antibodies for treatment of vitiligo. I.H. is a consultant to Abbvie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Union therapeutics, Novartis, Jansen, Avita, and Galderma and is investigator for Lenicura, Pfizer, Incyte, Avita and L\u2019Oreal\/La Roche-Posay. He is also a board member and past-president of the Hidradenitis Suppurativa Foundation and the Global Vitiligo Foundation. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}